

Claims

1. A polymorphic form of a mesylate salt of N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl)prop-2-enamide, which has an X-ray powder diffraction pattern with at least one specific peak at 2-theta = 7.2°, plus or minus 0.2° 2-theta, measured using CuKα radiation.
2. A polymorphic form of a mesylate salt of N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl)prop-2-enamide, which has an X-ray powder diffraction pattern with at least one specific peak at 2-theta = 8.6°, plus or minus 0.2° 2-theta, measured using CuKα radiation.
3. A polymorphic form of the mesylate salt of N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl)prop-2-enamide, as claimed in claim 1 or claim 2, which has an X-ray powder diffraction pattern with at least two specific peaks at 2-theta = 7.2° and 8.6°, where said values may be plus or minus 0.2° 2-theta, measured using CuKα radiation.
4. A polymorphic form of the mesylate salt of N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl)prop-2-enamide, as claimed in any one of claims 1 to 3, which has an X-ray powder diffraction pattern with specific peaks at 2-theta = 7.2, 8.6, 15.3, 10.4, 25.7, 26.1, 16.4, 9.5, 22.1 and 18.8° wherein said values may be plus or minus 0.2° 2-theta, measured using CuKα radiation.
5. A polymorphic form of the mesylate salt of N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl)prop-2-enamide, which has an X-ray powder diffraction pattern substantially the same as the X-ray diffraction pattern shown in Figure 20 when measured using CuKα radiation.